

Sino Biopharmaceutical Limited

Climate Risk Management Policy

1. Outline

Sino Biopharmaceutical Limited together with its subsidiaries (hereinafter referred to as "Sino Biopharmaceutical", "the Group") has always adhered to the strategy of responsible development and integrated "green and low-carbon" into its corporate genes. By referring to the guidelines of the Task Force on Climate-Related Financial Disclosures (TCFD) and the Climate Information Disclosure Guidelines of the Hong Kong Stock Exchange, and combining with the characteristics of our own business and operations, the Group establishes a climate change governance system, proactively identify and respond to various risks faced by the Group due to climate change, formulate special measures to deal with climate risks, and plan the low-carbon development path.

2. Applicability

The policy applies to the Group.

3. Climate Risk Governance

Sino Biopharmaceutical's climate risk governance structure is based on the ESG work organization structure of the Group, which establishes a comprehensive governance system from the board of directors to member companies to promote the implementation of the Group's climate strategy and climate risk management-related affairs.

- The Board of Directors: take the highest responsibility for the Group's response to climate change, and approve the Group's climate change strategy and objectives;
- ESG Work Management Committee: Comprehensively lead and manage the climate risk management work of the Group and member companies, regularly discuss climate change related issues and monitor climate risks, supervise and review the company's climate change response and the achievement of climate targets, regularly report to the board of directors and make suggestions to support the board's oversight and decision-making on climate change related issues;
- Member companies: responsible for coordinating the daily climate risk management and implementation of the company.

4. Climate Risk Identification and Management

Sino Biopharmaceutical regularly collects and identifies climate physical and transformation risks/opportunities that are affected by climate change on production and operation of the group, evaluate the causes and impact degree of

risks/opportunities, prepares identification lists of climate risks/opportunities, carries out qualitative and quantitative analysis of various risks according to the list of risks/opportunities, carries out significant assessment and prioritization, and on this basis, formulates corresponding countermeasures and strategies for climate risks and opportunities. Based on the results of regular risk assessment, Sino Biopharmaceutical has integrated climate risk management into the Group's overall risk management system to systematically and scientifically manage climate risk.

5. Climate Action

Based on the risk identification and assessment results, Sino Biopharmaceutical has carried out actions at the three levels of strategic adjustment, mitigation and adaptation to fully cope with the impact of climate change.

6. Supplementary Provisions

Anything not covered in this policy, or contrary to the relevant laws, regulations, or normative documents of the People's Republic of China, should be implemented in accordance with the relevant laws, regulations, or normative documents of the People's Republic of China.